Encouraging Initial Clinical Data Presented from Ph 1 Trial of THE001
“Presenting the first clinical data for THE001 in combination with regional hyperthermia is an important milestone for Thermosome,” said Dr. Frank Hermann, CMO of Thermosome. “The data not only confirm the galenic principle of thermosensitive liposomes releasing almost complete doxorubicin upon heat-triggered regional hyperthermia in humans, but also the safe application to date with no formulation-related adverse events. In addition, the first signs of clinical activity in these heavily pre-treated palliative patients are very encouraging and support our efforts to accelerate the clinical development program in soft tissue sarcoma.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the